Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Dynavax Technologies Corporation    DVAX

DYNAVAX TECHNOLOGIES CORPORATION (DVAX)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 01/15 04:00:00 pm
12.01 USD   +11.20%
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial Condition

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 04:26pm EST

Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition

Dynavax Technologies Corporation (”Dynavax”) announced in its presentation at the J.P. Morgan 37th Annual Healthcare Conference in San Francisco, California that it expects sales of HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the fiscal quarter ended December 31, 2018 to be no less than $3.7 million. This amount is preliminary, unaudited, subject to change upon completion of our audit, and may differ from what will be reflected in our audited consolidated financial statements as of and for the quarter and year ended December 31, 2018. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of December 31, 2018.

The information with respect to item 2.02 in this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

About Dynavax Technologies Corporation (NASDAQ:DVAX)

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

The post Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial Condition appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DYNAVAX TECHNOLOGIES CORPO
01/11DYNAVAX TECHNOLOGIES CORP : Results of Operations and Financial Condition (form ..
AQ
01/09DYNAVAX TECHNOLOGIES : Sams Club and Dynavax Technologies Corporation Announce C..
AQ
01/08Sam's Club and Dynavax Technologies Corporation Announce Collaboration to Mak..
GL
01/03Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
GL
2018DYNAVAX TECHNOLOGIES CORP : Other Events (form 8-K)
AQ
2018DYNAVAX TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
2018DYNAVAX TECHNOLOGIES CORP : Results of Operations and Financial Condition, Finan..
AQ
2018DYNAVAX TECHNOLOGIES : 3Q Earnings Snapshot
AQ
2018Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B ..
GL
2018Dynavax to Host Third Quarter 2018 Financial Results Conference Call
GL
More news
Financials ($)
Sales 2018 6,31 M
EBIT 2018 -152 M
Net income 2018 -158 M
Finance 2018 77,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 95,1x
EV / Sales 2019 8,82x
Capitalization 677 M
Chart DYNAVAX TECHNOLOGIES CORPORATION
Duration : Period :
Dynavax Technologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYNAVAX TECHNOLOGIES CORPO
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 35,6 $
Spread / Average Target 230%
EPS Revisions
Managers
NameTitle
Eddie J. Gray Chief Executive Officer & Director
Arnold Lewis Oronsky Chairman
David F. Novack Senior Vice President-Operations & Quality
Michael S. Ostrach Chief Financial & Business Officer, Senior VP
Robert L. Coffman Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
DYNAVAX TECHNOLOGIES CORPORATION31.58%677
GILEAD SCIENCES9.54%86 996
VERTEX PHARMACEUTICALS10.98%47 000
REGENERON PHARMACEUTICALS8.44%42 607
GENMAB-2.44%9 847
SAREPTA THERAPEUTICS INC8.80%7 925